PMID- 20158098
OWN - NLM
STAT- MEDLINE
DCOM- 20100326
LR  - 20110727
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 2
DP  - 2010 Feb
TI  - [A target of PPARgamma agonist: diabetes mellitus].
PG  - 284-93
AB  - The members of the PPARgamma agonists, such as the thiazolidinediones, act as 
      insulin sensitizer and improve insulin resistance. Several clinical studies have 
      evaluated the efficacy of PPARgamma agonists in the management of insulin 
      resistance and type 2 diabetes mellitus (T2DM). They are believed to improve 
      insulin resistance by stimulating differentiation of small adipocytes, 
      normalizing serum adipocytokine profile, and protecting pancreatic beta cells. 
      They also possess powerful anti-atherogenic potency through amelioration of lipid 
      profile and their anti-inflammatory effects. The PROactive study demonstrated 
      that pioglitazone protects against hard end-point of macrovascular events in T2DM 
      patients with previous macrovascular disease. A number of studies have also 
      proven the potency of PPARgamma agonists in the prevention of onset of T2DM.
FAU - Hashiramoto, Mitsuru
AU  - Hashiramoto M
AD  - Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical 
      School.
FAU - Kaku, Kohei
AU  - Kaku K
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (PPAR gamma)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - PPAR gamma/*agonists
RF  - 51
EDAT- 2010/02/18 06:00
MHDA- 2010/03/27 06:00
CRDT- 2010/02/18 06:00
PHST- 2010/02/18 06:00 [entrez]
PHST- 2010/02/18 06:00 [pubmed]
PHST- 2010/03/27 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Feb;68(2):284-93.